DV
Dividend Vision

APTN — APTN

APTN (APTN)

Total return is 12.0% over the past 0.2 years, 10.5 points ahead of SPY at 1.5%.

Adaptin Bio is a biotechnology company developing drug delivery technologies designed to deliver drugs directly to target destinations within the body, with a focus on treating intracerebral malignancies such as gliomas using its Brain Bispecific T-cell Engager platform. The company also develops APTN-101, a proprietary therapy targeting epidermal growth factor receptor variant III to treat aggressive malignant gliomas. As an early-stage biotech company, it does not currently distribute dividends.

APTN key facts

Asset type
Stock
Asset class
Equity
Inception date
05/14/2026
Distribution frequency
None
Last close
$6.27
Average volume
150.0
Payout ratio
0.0
Forward P/E
0.0